• Explore /
  • Poster
  • / High-dose interleukin-2 (HD IL-2) for metastatic renal CELL carcinoma (mRCC): Contemporary utilization trends in the United States.

High-dose interleukin-2 (HD IL-2) for metastatic renal CELL carcinoma (mRCC): Contemporary utilization trends in the United States.

Abstract Poster

Authors

null

Christopher B. Allard

Harvard Fellowship in Urologic Oncology, Boston, MA

Christopher B. Allard , Francisco Gelpi-Hammerschmidt , Lauren Christine Harshman , Izak Faiena , Parth K Modi , Benjamin I. Chung , Eric A. Singer , Steven L. Chang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Renal Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 449)

DOI

10.1200/jco.2015.33.7_suppl.449

Abstract #

449

Poster Bd #

D24

Abstract Disclosures

Similar Posters

First Author: Leonard Joseph Appleman

Poster

2016 Genitourinary Cancers Symposium

Experience with IL-2 in metastatic renal cell carcinoma after treatment with one or more targeted therapies.

Experience with IL-2 in metastatic renal cell carcinoma after treatment with one or more targeted therapies.

First Author: Hanh P. Mai

First Author: Antoine Thiery-Vuillemin

First Author: Jennifer O'Neil